Abeona Therapeutics and Beacon Therapeutics Announce Non-Exclusive Agreement for Beacon to Evaluate Therapeutic Potential of Abeona's Patented AAV204 Capsid for Select Ophthalmology Indications
July 11, 2024 07:30 ET
|
Abeona Therapeutics Inc.
CLEVELAND and LONDON, July 11, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a cell and gene therapy company with proprietary adeno-associated virus (AAV)-based capsids, and...
Clearside Biomedical Appoints Dr. Glenn Yiu to its Scientific Advisory Board
July 11, 2024 07:05 ET
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., July 11, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the...
Centers for Medicare and Medicaid Propose New Reimbursement for EXPAREL in All Outpatient Surgical Environments Beginning January 1, 2025
July 10, 2024 16:19 ET
|
Pacira BioSciences
-- Proposed Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment System Rule extends separate payment from ambulatory surgical centers to include the hospital outpatient...
Adverum Biotechnologies to Host Webcast to Review Clinical Data from the 26-Week Interim Analysis of the Ongoing LUNA Phase 2 Trial in Wet AMD Being Presented at ASRS Annual Meeting
July 10, 2024 08:00 ET
|
Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., July 10, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly...
Ocuphire Pharma to Highlight APX3330 for Diabetic Retinopathy at Two Scientific Meetings in July
July 10, 2024 08:00 ET
|
Ocuphire Pharma
CEO to participate in ARVO SIG panel on oral medications for retinal diseases ZETA-1 Phase 2 clinical trial subset analysis to be presented during the ASRS 42nd Annual Scientific Meeting FARMINGTON...
United States Ophthalmology KOLs Fair-Market Value Compensation Rates Report: An Independent Reference for Negotiations with Thought Leaders (KOLs) and Healthcare Providers (HCPs)
July 10, 2024 04:24 ET
|
Research and Markets
Dublin, July 10, 2024 (GLOBE NEWSWIRE) -- The "Fair-Market Value Compensation Rates for Ophthalmology KOLs - United States" report has been added to ResearchAndMarkets.com's offering. Thought...
Essential Pharma launches campaign with International Health Partners to donate life-saving medicines to disaster-hit countries
July 10, 2024 02:00 ET
|
Essential Pharma
Essential Pharma launches campaign with International Health Partners to donate life-saving medicines to disaster-hit countries Donations to help support over 30,000 patients in disaster-hit and...
Opthea Announces Publication on VEGF-C and D Signaling Pathways as Potential Targets for Treatment of Wet AMD
July 09, 2024 07:30 ET
|
Opthea Limited
Research underpins sozinibercept’s potential as novel, first-in-class VEGF-C/D ‘trap’ to prevent blood vessel growth and vascular leakage in the retina Published in peer-reviewed journal...
Apellis Announces Five Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting
July 09, 2024 07:00 ET
|
Apellis Pharmaceuticals, Inc.
Late-breaking presentation shows SYFOVRE® (pegcetacoplan injection) demonstrated visual function benefit on prespecified endpoint in GALE long-term extension study WALTHAM, Mass., July 09, 2024 ...
Roche to reintroduce Susvimo in the US for people with neovascular age-related macular degeneration (nAMD)
July 08, 2024 11:45 ET
|
F. Hoffmann-La Roche Ltd
The FDA has approved updates to Susvimo, which will be available to US retina specialists and patients with nAMD in the coming weeksSusvimo offers the first alternative to regular eye injections that...